Countable Labs reported progress on a PCR platform designed for single-molecule precision quantification, aiming to improve sensitivity and run-to-run reproducibility versus conventional statistical PCR readouts. The company’s focus is on addressing ambiguity in rare-event detection, including applications such as viral titer, vector copy number, residual DNA impurities, circulating tumor DNA, and minimal residual disease measurements. In the report, CEO Giovanna Prout highlights that many PCR approaches rely on statistical inference rather than direct molecule counts, which can create variability when setting clinical thresholds or comparing results across sites. Single-molecule counting is positioned as a route to more definitive measurement in sensitive clinical and biomanufacturing settings. The story frames the platform as a measurement-standards enabler for next-generation gene and cell therapy quality control where low-frequency events and comparability are critical.